Effect of sitagliptin on metabolic abnormalities in schizophrenic patients treating with olanzapine
Phase 3
Recruiting
- Conditions
- Metabolic abnormalities in schizophrenic patients treating with olanzapine.
- Registration Number
- IRCT20191210045677N1
- Lead Sponsor
- Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Diagnosis of schizophrenia based on DSM-5 criteria and clinical interview
treating with olanzapine
Exclusion Criteria
Diagnosis of other mental disorders
Major medical problems(cardiovascular,pulmonary,gasterointestinal,renal)
Substance use
Pregnancy
Premorbid or comorbid metabolic abnormalities(obesity,diabetes,hypertension,hyperlipidemia)
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Blood sugar. Timepoint: At beginning,week 4 and week 12 of study. Method of measurement: Measurement of fasting blood sugar via laboratatory tests.;Weight. Timepoint: At beginning,week 4 and week 12 of study. Method of measurement: weight measurement with balance.;Lipid profile. Timepoint: At beginning,week 4 and week 12 of study. Method of measurement: Measurement of fasting blood lipids via laboratory tests.;Waist circumference. Timepoint: At beginning,week 4 and week 12 of study. Method of measurement: Measurement by meter.;Blood pressure. Timepoint: At beginning, week 4 and week 12 of study. Method of measurement: Measurement of blood pressure by Mercury barometer.
- Secondary Outcome Measures
Name Time Method . Timepoint: . Method of measurement: .